Evidence map›Paper›PMID 40649966›Full record

ArticleInternational journal of molecular sciences2025

The Production of Recombinant Azurin from

Tomasz Kowalczyk, Anna Merecz-Sadowska, Ewelina Synowiec, Tomasz Śliwiński, Janusz Piekarski, Janusz Szemraj, Mattia Mori, Patricia Rijo, Przemysław Sitarek

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tomasz KowalczykDepartment of Molecular Biotechnology and Genetics, University of Lodz, 90-237 Lodz, Poland.ORCID 0000-0002-4559-5015
Anna Merecz-SadowskaDepartment of Economic and Medical Informatics, University of Lodz, 90-214 Lodz, Poland.ORCID 0000-0001-9987-4573
Ewelina SynowiecDepartment of Molecular Genetics, University of Lodz, 90-236 Lodz, Poland.ORCID 0000-0002-0730-4491
Tomasz ŚliwińskiDepartment of Molecular Genetics, University of Lodz, 90-236 Lodz, Poland.ORCID 0000-0001-8385-7744
Janusz PiekarskiDepartment of Surgical Oncology, Medical University in Lodz, 93-513 Lodz, Poland.
Janusz SzemrajDepartment of Medical Biochemistry, Medical University of Lodz, 92-2156 Lodz, Poland.ORCID 0000-0001-6052-3557
Mattia MoriDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy.ORCID 0000-0003-2398-1254
Patricia RijoCBIOS-Research Center for Biosciences & Health Technologies, Universidade Lusófona de Humanidades e Tecnologias, 1749-024 Lisbon, Portugal.ORCID 0000-0001-7992-8343
Przemysław SitarekDepartment of Medical Biology, Medical University of Lodz, 90-151 Lodz, Poland.ORCID 0000-0001-5495-3550

Funding

University of Lodz IDUB021DO
6 · The paper itself

Abstract

Azurin is a copper-containing redox protein naturally produced by

Indexed as

Antineoplastic AgentsApoptosisAzurinBreast NeoplasmsPseudomonas aeruginosaAnimalsCell Line, TumorFemaleHumansMCF-7 CellsMembrane Potential, MitochondrialMolecular Docking SimulationReactive Oxygen SpeciesRecombinant ProteinsAntineoplastic AgentsAzurinReactive Oxygen SpeciesRecombinant Proteinsanticancerapoptosisazurinbreast cancerrecombinant proteins

Identifiers

PMID40649966
PMCPMC12250392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.